Biotechnology microcap Xtrana Inc. has put itself under the strategic alternatives review microscope, and has retained West Ridge Associates LLC to help with its research, which includes a possible sale of the company. Los Angeles-based West Ridge provides investment banking services, including M&A, to early-stage and middle-market life sciences companies. Charles Troe, the banker working on behalf of Xtrana, said the review was “substantially complete” and he expected the company to know its direction within the next 60 days. Troe declined to give the exact number of books sent on the $3 million market cap company.
To read the entire story, you must be logged in.
Please log in now or register with us.
